SPI-339 is an orally available small molecule drug that has potential applications for the treatment of attention disorders, memory acquisition and other cognitive functions. The company hopes that the drug will be of particular use in the treatment of attention deficit and hyperactivity disorder (ADHA).
When the patent is issued, it will protect the drug for use in the treatment of ADHD and other neurological disorders until the year 2021.
“We are happy to receive this notice of allowance on SPI-339,” stated Dr Rajesh Shrotriya, Chairman, CEO and president of Spectrum Pharmaceuticals. “This patent, when issued, will be a significant addition to our intellectual property portfolio on our Central Nervous System (CNS) compounds.”